Provence Technologies and NexGenix announce successful lead compound development
Provence Technologies, a service provider in fine organic chemistry, and NexGenix Pharmaceuticals, a discovery and development company focused on the "next generation" of targeted therapies for cancer and diseases of the nervous system, announced a successful collaboration for the production of NexGenix's lead compound.
NexGenix and Provence Technologies have been collaborating on the synthesis optimization and pre industrialization of this innovative molecule targeting Hsp90. Hsp90 is a member of the heat shock protein family which assists in protein folding, cell signaling, and tumor repression and is a novel target for oncology and neurodegenerative disorders. The new generation molecule, initially developed by Prof Nicolas Winssinger at Université de Strasbourg, has demonstrated efficacy in numerous oncology models.
Working within very tight schedules, Provence Technologies have successfully produced material required for preclinical testing and IND enabling studies, to enable NexGenix to achieve its IND filing goals. "Working with Provence Technologies has given us the opportunity to achieve our timelines for our lead program, while at the same time using their substantial experience to reduce costs in the process, even at this early stage of development," said Allan Rubenstein, NexGenix's CEO.
Provence Technologies works on the basis that having a good molecule for a precisely characterized in-vitro target is not enough to make a successful drug. If process issues are not identified at a very early stage of the development program, if the chemical pathway is not designed and optimized to allow process improvements to be planned and realized for the future, and if production cannot be maintained through the early phase of the development cycle, the chances of project failure are high - even if the compound proves itself to be very active.
Other news from the department research and development
